Tags

Type your tag names separated by a space and hit enter

Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (>80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population.
BMC Urol. 2015 Apr 16; 15:33.BU

Abstract

BACKGROUND

Currently, large prostate size (>80 mL) of benign prostatic hyperplasia (BPH) still pose technical challenges for surgical treatment. This prospective study was designed to explore the safety and efficacy of prostatic arterial embolization (PAE) as an alternative treatment for patients with lower urinary tract symptoms (LUTS) due to largeBPH.

METHODS

A total of 117 patients with prostates >80 mL were included in the study; all were failure of medical treatment and unsuited for surgery. PAE was performed using combination of 50-μm and 100-μm particles in size, under local anaesthesia by a unilateral femoral approach. Clinical follow-up was performed using the international prostate symptoms score (IPSS), quality of life (QoL), peak urinary flow (Qmax), post-void residual volume (PVR), international index of erectile function short form (IIEF-5), prostatic specific antigen (PSA) and prostatic volume (PV) measured by magnetic resonance (MR) imaging, at 1, 3, 6 and every 6 months thereafter.

RESULTS

The prostatic artery origins in this study population were different from previously published results. PAE was technically successful in 109 of 117 patients (93.2%). Follow-up data were available for the 105 patients with a mean follow-up of 24 months. The clinical improvements in IPSS, QoL, Qmax, PVR, and PV at 1, 3, 6, 12, and 24 months was 94.3%, 94.3%, 93.3%, 92.6%, and 91.7%, respectively. The mean IPSS (pre-PAE vs post-PAE 26.0 vs 9.0; P < .0.01), the mean QoL (5.0 vs 3.0; P < 0.01), the mean Qmax (8.5 vs 14.5; P < 0.01), the mean PVR (125.0 vs 40.0; P < 0.01), and PV (118.0 vs 69.0, with a mean reduction of 41.5%; P < 0.01) at 24-month after PAE were significantly different with respect to baseline. The mean IIEF-5 was not statistically different from baseline. No major complications were noted.

CONCLUSIONS

PAE is a safe and effective treatment method for patients with LUTS due to large volume BPH. PAE may play an important role in patients in whom medical therapy has failed, who are not candidates for open surgery or TURP or refuse any surgical treatment.

Authors+Show Affiliations

Department of Interventional Radiology, Chinese PLA General Hospital Beijing, 100853, Beijing, People's Republic of China. wangmq@vip.sina.com.Department of Interventional Radiology, Chinese PLA General Hospital Beijing, 100853, Beijing, People's Republic of China. guoliping7521@126.com.Department of Interventional Radiology, Chinese PLA General Hospital Beijing, 100853, Beijing, People's Republic of China. guodongbear@sina.com.Department of Interventional Radiology, Chinese PLA General Hospital Beijing, 100853, Beijing, People's Republic of China. yuankai80601@126.com.Department of Interventional Radiology, Chinese PLA General Hospital Beijing, 100853, Beijing, People's Republic of China. 301likai@sina.com.Department of Interventional Radiology, Chinese PLA General Hospital Beijing, 100853, Beijing, People's Republic of China. duanfeng@vip.sina.com.Department of Interventional Radiology, Chinese PLA General Hospital Beijing, 100853, Beijing, People's Republic of China. mczlks@sina.com.Department of Interventional Radiology, Chinese PLA General Hospital Beijing, 100853, Beijing, People's Republic of China. wang_yan_301@163.com.Department of Interventional Radiology, Chinese PLA General Hospital Beijing, 100853, Beijing, People's Republic of China. xhkhy@163.com.Department of Interventional Radiology, Chinese PLA General Hospital Beijing, 100853, Beijing, People's Republic of China. 13811023876@163.com.

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25887036

Citation

Wang, Mao Qiang, et al. "Prostatic Arterial Embolization for the Treatment of Lower Urinary Tract Symptoms Due to Large (>80 mL) Benign Prostatic Hyperplasia: Results of Midterm Follow-up From Chinese Population." BMC Urology, vol. 15, 2015, p. 33.
Wang MQ, Guo LP, Zhang GD, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (>80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population. BMC Urol. 2015;15:33.
Wang, M. Q., Guo, L. P., Zhang, G. D., Yuan, K., Li, K., Duan, F., Yan, J. Y., Wang, Y., Kang, H. Y., & Wang, Z. J. (2015). Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (>80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population. BMC Urology, 15, 33. https://doi.org/10.1186/s12894-015-0026-5
Wang MQ, et al. Prostatic Arterial Embolization for the Treatment of Lower Urinary Tract Symptoms Due to Large (>80 mL) Benign Prostatic Hyperplasia: Results of Midterm Follow-up From Chinese Population. BMC Urol. 2015 Apr 16;15:33. PubMed PMID: 25887036.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (>80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population. AU - Wang,Mao Qiang, AU - Guo,Li Ping, AU - Zhang,Guo Dong, AU - Yuan,Kai, AU - Li,Kai, AU - Duan,Feng, AU - Yan,Jie Yu, AU - Wang,Yan, AU - Kang,Hai Yan, AU - Wang,Zhi Jun, Y1 - 2015/04/16/ PY - 2014/11/26/received PY - 2015/03/31/accepted PY - 2015/4/19/entrez PY - 2015/4/19/pubmed PY - 2016/3/5/medline SP - 33 EP - 33 JF - BMC urology JO - BMC Urol VL - 15 N2 - BACKGROUND: Currently, large prostate size (>80 mL) of benign prostatic hyperplasia (BPH) still pose technical challenges for surgical treatment. This prospective study was designed to explore the safety and efficacy of prostatic arterial embolization (PAE) as an alternative treatment for patients with lower urinary tract symptoms (LUTS) due to largeBPH. METHODS: A total of 117 patients with prostates >80 mL were included in the study; all were failure of medical treatment and unsuited for surgery. PAE was performed using combination of 50-μm and 100-μm particles in size, under local anaesthesia by a unilateral femoral approach. Clinical follow-up was performed using the international prostate symptoms score (IPSS), quality of life (QoL), peak urinary flow (Qmax), post-void residual volume (PVR), international index of erectile function short form (IIEF-5), prostatic specific antigen (PSA) and prostatic volume (PV) measured by magnetic resonance (MR) imaging, at 1, 3, 6 and every 6 months thereafter. RESULTS: The prostatic artery origins in this study population were different from previously published results. PAE was technically successful in 109 of 117 patients (93.2%). Follow-up data were available for the 105 patients with a mean follow-up of 24 months. The clinical improvements in IPSS, QoL, Qmax, PVR, and PV at 1, 3, 6, 12, and 24 months was 94.3%, 94.3%, 93.3%, 92.6%, and 91.7%, respectively. The mean IPSS (pre-PAE vs post-PAE 26.0 vs 9.0; P < .0.01), the mean QoL (5.0 vs 3.0; P < 0.01), the mean Qmax (8.5 vs 14.5; P < 0.01), the mean PVR (125.0 vs 40.0; P < 0.01), and PV (118.0 vs 69.0, with a mean reduction of 41.5%; P < 0.01) at 24-month after PAE were significantly different with respect to baseline. The mean IIEF-5 was not statistically different from baseline. No major complications were noted. CONCLUSIONS: PAE is a safe and effective treatment method for patients with LUTS due to large volume BPH. PAE may play an important role in patients in whom medical therapy has failed, who are not candidates for open surgery or TURP or refuse any surgical treatment. SN - 1471-2490 UR - https://www.unboundmedicine.com/medline/citation/25887036/Prostatic_arterial_embolization_for_the_treatment_of_lower_urinary_tract_symptoms_due_to_large__>80_mL__benign_prostatic_hyperplasia:_results_of_midterm_follow_up_from_Chinese_population_ L2 - https://bmcurol.biomedcentral.com/articles/10.1186/s12894-015-0026-5 DB - PRIME DP - Unbound Medicine ER -